NASDAQ:DNTH Dianthus Therapeutics Q4 2025 Earnings Results & Report $86.03 +3.02 (+3.64%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$89.23 +3.20 (+3.72%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dianthus Therapeutics missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released March 9, 2026. The company reported EPS of -$1.43 versus the -$0.97 consensus estimate, while revenue of $568 thousand topped the $398 thousand estimate by $170.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Dianthus Therapeutics EPS ResultsActual EPS-$1.43Consensus EPS -$0.97Beat/MissMissed by -$0.46One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersDianthus Therapeutics Revenue ResultsActual Revenue$568 thousandExpected Revenue$398 thousandBeat/MissBeat by +$170.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Dianthus Therapeutics Q4 2025 Earnings FAQ Did Dianthus Therapeutics beat earnings estimates for Q4 2025? Dianthus Therapeutics (NASDAQ:DNTH) reported earnings of -$1.43 per share for Q4 2025, missing the consensus estimate of -$0.97. The report was announced on Monday, March 9, 2026. What was Dianthus Therapeutics' revenue for Q4 2025? Dianthus Therapeutics reported revenue of $568 thousand for Q4 2025, against a consensus estimate of $398 thousand. Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial ResultsNovember 4, 2026 | finance.yahoo.comDianthus Therapeutics (DNTH) Projected to Announce Earnings on ThursdayNovember 4, 2026 | americanbankingnews.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 8 at 1:00 AM | Behind the Markets (Ad)Dianthus Therapeutics Inc DNTHNovember 3, 2026 | morningstar.comMDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 2, 2026 | globenewswire.comDianthus Therapeutics to Participate in Five Investor Conferences During NovemberNovember 2, 2026 | globenewswire.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH) is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated. Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway. The company is evaluating DNTH103 as a potential treatment for complement-mediated disorders, including generalized myasthenia gravis and immune-mediated neuropathies such as chronic inflammatory demyelinating polyneuropathy. The company was established to advance next-generation complement-targeted therapies intended to offer durable activity and convenient administration. Dianthus is headquartered in the United States and conducts clinical development activities aimed at serving patients with serious autoimmune diseases in major global healthcare markets.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?The Ugly Truth Behind SoundHound’s Q3 ResultsSandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
